Reports Q4 revenue $269.1M, consensus $266.22M. “We are very excited with the strong finish to 2025. The team made excellent progress with the Inspire V launch, with clinical insights from the early phase of commercial adoption continuing to validate positive patient outcomes and improvements in therapy delivery,” said Tim Herbert, CEO of Inspire Medical (INSP) Systems. “Despite the dynamic reimbursement landscape, our strong fourth quarter execution positions us well as we enter 2026.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- INSP Upcoming Earnings Report: What to Expect?
- Inspire Medical price target lowered to $89 from $91 at UBS
- Inspire Medical downgraded to Sector Perform from Outperform at RBC Capital
- Truist downgrades Inspire Medical as coding uncertainty takes upside off table
- Inspire Medical downgraded to Hold from Buy at Truist